The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.
Sponsor: Seoul National University Bundang Hospital
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Seoul National University Bundang Hospital
- Acute Kidney Injury · Phase NA · Feb 2026
- Hemiplegia · Phase NA · Sep 2022
- Arthritis Knee · Phase PHASE4 · Mar 2018
- Postoperative Pain · Phase NA · Nov 2017
- Insulin Resistance · Phase PHASE3 · Jan 2016
See all terminations from Seoul National University Bundang Hospital
Listed as NCT02359331, this NA trial focuses on Helicobacter Infection and remains terminated or withdrawn. Sponsored by Seoul National University Bundang Hospital, it has been updated 10 times since 2014, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated NA
-
Sep 2024 — Sep 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
May 2023 — Jul 2024 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Apr 2023 — May 2023 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Apr 2021 — Apr 2023 [monthly]
Recruiting NA
-
Jan 2021 — Apr 2021 [monthly]
Recruiting NA
-
May 2019 — Jan 2021 [monthly]
Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seoul National University Bundang Hospital
For direct contact, visit the study record on ClinicalTrials.gov .